Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 16;14(20):2293.
doi: 10.3390/diagnostics14202293.

Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy

Marcel Figueras  1   2   3 , Lourdes Mengual  1   2   3 , Mercedes Ingelmo-Torres  1   2 , Fiorella L Roldán  1   2 , Bernat Padullés  1   2 , Héctor Alfambra  1 , Sandra Herranz  1 , Pilar Paredes  2   4   5 , Gary Amseian  6 , Joel Mases  7 , Maria J Ribal  1   2   8 , Laura Izquierdo  1   2   8 , Antonio Alcaraz  1   2   8
Affiliations

Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy

Marcel Figueras et al. Diagnostics (Basel). .

Abstract

Background/Objectives: Currently, the prediction of disease recurrence after radical prostatectomy (RP) in localized prostate cancer (PCa) relies on clinicopathological parameters, which lack accuracy in predicting clinical outcomes. This study focused on evaluating the utility of cfDNA levels and fragmentation patterns as prognostic biomarkers in progressive prostate-specific antigen (PSA) patients, including those with persistent PSA and biochemical recurrence (BR), after primary treatment in localized PCa patients. Methods: Twenty-nine high-risk localized PCa patients were enrolled in the study between February 2022 and May 2023. Blood samples were obtained before robotic RP. cfDNA concentration and fragment size were quantified using the Quant-it PicoGreen dsDNA Assay kit and Agilent 2200 TapeStation System, respectively. Results: The mean PSA value at diagnosis was 9.4 ng/mL. Seven patients (24.1%) had stage pT2 and 22 (75.9%) pT3. Nine patients (31%) had detectable PSA at the first PSA control six weeks after surgery, and four patients (20%) had BR during a mean follow-up of 18.4 months. No associations were found between cfDNA levels or fragmentation patterns and clinicopathological data. Although not statistically significant, patients with detectable PSA levels post-surgery exhibited higher cfDNA levels and shorter fragments compared with those with undetectable PSA. Conclusions: Our study indicated a tendency toward more fragmented cfDNA levels in PCa patients with persistent PSA. Strikingly, biochemical recurrent PCa patients exhibited similar cfDNA levels and fragmentation patterns compared to non-recurrent patients. Further studies exploring liquid biopsy-derived biomarkers in localized PCa patients are needed to elucidate their clinical utility in predicting PSA persistence.

Keywords: biomarker; cell-free DNA; liquid biopsy; localized prostate cancer; persistent PSA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Box plots describing (A) cfDNA levels and (B) mean fragmentation patterns for PC patients with PSA detectable after surgery.
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Ferraro S., Bussetti M., Panteghini M. Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. Clin. Chem. 2021;67:602–609. doi: 10.1093/clinchem/hvab002. - DOI - PubMed
    1. Ferraro S., Biganzoli D., Rossi R.S., Palmisano F., Bussetti M., Verzotti E., Gregori A., Bianchi F., Maggioni M., Ceriotti F., et al. Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratio. Clin. Chem. Lab. Med. (CCLM) 2023;61:1327–1334. doi: 10.1515/cclm-2023-0008. - DOI - PubMed
    1. Sandhu S., Moore C.M., Chiong E., Beltran H., Bristow R.G., Williams S.G. Prostate cancer. Lancet. 2021;398:1075–1090. doi: 10.1016/S0140-6736(21)00950-8. - DOI - PubMed
    1. Mottet N., van den Bergh R.C.N., Briers E., Van den Broeck T., Cumberbatch M.G., De Santis M., Fanti S., Fossati N., Gandaglia G., Gillessen S., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2021;79:243–262. doi: 10.1016/j.eururo.2020.09.042. - DOI - PubMed

LinkOut - more resources